
The CEO of a medical technology and diagnostics company discusses why individual testing for COVID-19 will be part of the landscape for the foreseeable future.

The CEO of a medical technology and diagnostics company discusses why individual testing for COVID-19 will be part of the landscape for the foreseeable future.

Diane Bryant, CEO of NovaSignal, details the advances seen in the NovaGuide 2 platform

A leader in the transition to value-based care answers questions about a point-of-care option.

Research shows medical device companies provide higher payments than drug companies to physicians, but greater research is needed to understand the relationships and how they could impact consumer welfare.

Known by different names around the globe, from vaccine passports or green passes, various digital certificates confirm vaccination and negative SARS-CoV-2 test status through “confidential data transfers."

Sentiment among Blacks has shifted markedly since February, with 55% now having had their first shot or being willing to be vaccinated.

The calculation method used in the study accounted for heart failure and a patient’s history of opioid use, and found that that both respiratory depression and length of stay continued to cost.

Tara Vail, chief growth officer of HST Pathways, discusses the lack of EHRs at ambulatory surgery centers and the challenges to adoption.

A leading digital marketing firm acquires a market access consultancy and rebrands as a "healthcare innovation" entity.

Lalan Wilfong, MD, who leads value-based care initiatives for the 200-site oncology network, said the rollout of the Navigating Cancer platform has helped reduce incident resolution times 33%.

The tech improved asthma symptoms and caregiver quality of life but increased healthcare use.

Interoperability has been discussed for years, but a partnership between a specialty pharmacy solutions company and UVA Health shows how the ability to "talk to" electronic health records is finally happening.

The smartphone-controlled device demonstrated efficacy in a recent trial.

A study found 65% of patients would adopt remote monitoring capabilities even if they did not improve their diabetes.